Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109681 · ClinicalTrials.gov registry record · Phase 2
Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00109681 is a Phase 2 study that has completed, run by Actelion. The registered enrollment target is 50 participants.
The verdict
NCT00109681, a Phase 2 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether iloprost inhalation solution is safe in subjects with idiopathic pulmonary fibrosis (IPF) and elevated pulmonary arterial pressure. The secondary purpose is to evaluate the effectiveness of this treatment in subjects with this disease.
Interventions
- DRUG Iloprost Inhalation Solution (Ventavis)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109681
The ClinicalTrials.gov registry entry for NCT00109681 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iloprost Inhalation Solution (Ventavis) is the first listed.
NCT00109681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00109681 about?
NCT00109681 is a clinical study titled "Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis". The primary purpose of this study is to determine whether iloprost inhalation solution is safe in subjects with idiopathic pulmonary fibrosis (IPF) and elevated pulmonary arterial pressure. The secondary purpose is to evaluate the effectiveness of this treatment in subjects with this disease.
What is the current status of trial NCT00109681?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2005-04. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00109681?
The interventions under investigation include: Iloprost Inhalation Solution (Ventavis) (DRUG).
Who is sponsoring clinical trial NCT00109681?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.